Healthcare Industry News:  Elekta 

Devices Oncology

 News Release - January 6, 2009

TomoTherapy Tops MD Buyline Review of Radiation Therapy Vendors

“The uniqueness in design of the delivery system and software are staples of system performance,” states one user.

MADISON, Wis – Jan. 6, 2009 – (HSMN NewsFeed) - TomoTherapy Incorporated (NASDAQ: TOMO), maker of the Hi·Art® treatment system for advanced, CT platform-based radiation therapy, announced today that it has again earned the highest user satisfaction composite rating among linear accelerator vendors in MD Buyline’s Quarterly User Satisfaction Report, published on Jan. 1, 2009. The composite score for TomoTherapy topped that of conventional linear accelerator suppliers Varian Medical Systems, Elekta and Siemens for the third time in the last four quarters.

MD Buyline measures user satisfaction based on evaluations by more than 3,300 hospitals in the member network. Members rank their satisfaction in six areas: system performance; system reliability; installation and implementation; applications training; service response time; and service repair quality. TomoTherapy’s rankings were the highest in overall composite score, and either the highest or second highest in each contributing category. Founded in 1983, MD Buyline is a market intelligence organization that provides the healthcare industry with independent analysis and reporting.

In rating TomoTherapy, MD Buyline wrote, “TomoTherapy is the only vendor for the CT-based linear accelerator which delivers radiation dose in a helical or fan beam fashion. Elekta, Siemens and Varian offer IMRT and IGRT options on conventional linear accelerator systems.” Specific, anonymous user comments cited in the review include:
  • “The uniqueness in design of the delivery system and software are staples of system performance.”
  • “It is a great system; we have absolutely no regrets with this purchase.”
  • “We are extremely happy with the overall capabilities of this single system. We were originally concerned that it would not be able to do everything we needed, but it is capable of performing all necessary functions.”
  • “There are no issues to report with reliability.”
  • “We are very happy with our installation and set-up time. TomoTherapy got our system up and running in no time.”
Del Coufal, TomoTherapy’s vice president of marketing, said, “We are delighted that our customer satisfaction rankings have once again placed us ahead of the competition. Clearly, these cancer centers are pleased with their investment in the Hi·Art treatment system, the only device designed for image-guided, intensity-modulated radiotherapy (IG-IMRT), and the true platform of the future.” About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO.


Source: TomoTherapy

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.